Genmab A/S — Sponsor Intelligence | 28 EU Trials

Filter these 28 trials by condition, phase, country and more.

Open in Search →

28 Registered trials

6 Recruiting

22 Completed trials

21 Countries active

51 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I

Phase I (FiH)

Phase III: 5 Phase II: 5 Phase I/II: 4 Phase I: 5 Phase I (FiH): 9

Oversight events:

3 serious breaches 3 temporary halts 1 unexpected event across 5 trials

View oversight register →

100%

22 of 22 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Endometrial cancer 2 Non-small cell lung cancer metastatic 2 Non-small cell lung cancer 1 B-cell lymphoma refractory 1 Endometrial cancer recurrent 1 Neoplasm malignant 1 Ovarian cancer recurrent 1 Endometrial cancer metastatic 1 Ovarian cancer 1 Myelodysplastic syndrome with excess blasts 1 Cervix carcinoma 1 Malignant melanoma 1

Top IMPs

EPCORITAMAB 5 PEMBROLIZUMAB 5 ACASUNLIMAB 4 RINATABART SESUTECAN 4 PACLITAXEL ALBUMIN-BOUND 2 TECAGINLIMAB 2 CARBOPLATIN 1 CISPLATIN 1 DARATUMUMAB 1 ERZOTABART 1 GEN1046 1 GEN1047 1

All trials

28 total

Study to assess the efficacy and safety of Rina-S plus standard of care compared to standard of care for maintenance treatment of participan… Pending

2025-522167-15-00 Phase III 10 countries RINATABART SESUTECAN
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( R… Recruiting

2024-519818-31-01 Phase III 11 countries RINATABART SESUTECAN
A Study of GEN1106 in Participants with Solid Tumors Recruiting

2025-523760-21-00 Phase I 1 country
Study to assess the efficacy and safety of Rina-S in participants with non-small cell lung cancer Recruiting

2025-522107-18-00 Phase II 8 countries RINATABART SESUTECAN
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants with Advanced Solid Tumors Recruiting

2025-523931-21-00 Phase I 1 country
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (… Recruiting

2025-523101-15-00 Phase I 2 countries
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting

2024-514822-21-00 Phase III 12 countries RINATABART SESUTECAN
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended

2024-512998-27-00 Phase III 15 countries ACASUNLIMAB; MYCOPHENOLATE MOFETIL; PEMBROLIZUMAB; TOCILIZUMAB
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung… Ended

2024-513770-22-00 Phase II 7 countries ACASUNLIMAB; PEMBROLIZUMAB
A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended

2023-504830-23-00 Phase III 13 countries EPCORITAMAB
Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome Ended

2023-504828-25-00 Phase I/II 9 countries EPCORITAMAB; PIRTOBRUTINIB
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended

2023-504805-35-00 Phase I/II 10 countries EPCORITAMAB
GEN1042 Trial of Safety and Anti-tumor Activity in Subjects with Malignant Solid Tumors Ended

2023-508526-10-00 Phase I (FiH) 5 countries PACLITAXEL ALBUMIN-BOUND; TECAGINLIMAB
GEN1046 Safety Trial in Patients With Malignant Solid Tumors Ended

2023-509059-15-00 Phase I (FiH) 4 countries ACASUNLIMAB; CARBOPLATIN; CISPLATIN; PACLITAXEL ALBUMIN-BOUND; PEMBROLIZUMAB; PE…
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended

2023-504802-12-00 Phase I (FiH) 9 countries EPCORITAMAB
Trial to assess the safety and antitumor activity of GEN1057 on malignant solid tumors Ended

2024-513563-75-00 Phase I 1 country
A first-in-human trial of safety and efficacy of GEN1078 in participants with solid tumors. Ended

2024-515752-21-00 Phase I (FiH) 2 countries GEN1078
Trial to assess the safety and preliminary efficacy of GEN1055 on malignant solid tumors as monotherapy and as combination therapy. Ended

2023-507049-28-00 Phase I (FiH) 1 country GEN1055
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer Ended

2022-502453-33-00 Phase II 5 countries GEN1046; PEMBROLIZUMAB
A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects with Metastatic Solid Tumors Ended

2023-508529-29-00 Phase I/II 1 country TECAGINLIMAB
EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Ended

2023-504832-16-00 Phase II 8 countries EPCORITAMAB
Study of safety and antitumor activity of GEN1056 in participants with advanced solid tumors Ended

2024-514357-29-00 Phase I 1 country
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy and in Com… Ended

2022-502419-12-00 Phase I (FiH) 1 country GEN1053
GEN1047 for Solid Tumors - First in Human (FIH) Trial Ended

2024-510722-10-00 Phase I (FiH) 7 countries GEN1047

Showing 1–24 of 28 trials

← All sponsors A–Z